Patents by Inventor Andrew Justin Radcliffe Porter
Andrew Justin Radcliffe Porter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240035020Abstract: The present invention relates to a synthetic library of vvthumanised antigen specific binding molecules derived from a member of a species in the Elasmobranchii subclass, processes for the production thereof and specific antigen specific binding molecules isolated from said library. The present invention also relates to the multi-domain specific binding molecules comprising humanised Ig-like Novel Antigen Receptor variable domains (VNARs). Specific binding domains that bind to Tumour Necrosis Factor alpha (TNF?) are also provided.Type: ApplicationFiled: September 15, 2022Publication date: February 1, 2024Inventors: Caroline Jane BARELLE, Marina KOVALEVA, Laura Ann FERGUSON, Obinna Chukwuemeka UBAH, Andrew Justin Radcliffe PORTER
-
Publication number: 20230257452Abstract: The invention relates to specific binding molecules, such as antibodies, directed to key epitopes of tau. The specific binding molecules of the invention find applications in diagnostics and therapeutics of tauopathies including Alzheimer's disease.Type: ApplicationFiled: July 9, 2021Publication date: August 17, 2023Inventors: Charles Robert HARRINGTON, Soumya PALLIYIL SOMAN, Andrew Justin Radcliffe PORTER, Claude Michel WISCHIK, Mohammad ARASTOO, Lewis Kirk PENNY, Richard LOFTHOUSE
-
Patent number: 11459377Abstract: The present invention provides methods for the production of a library of antigen specific antigen binding molecules having a peptide domain structure represented by the following formula (I): FW 1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 comprising (1) isolating RNA from a member of a species in the Elasmobranchii subclass; (2) amplifying DNA sequences from RNA obtained; (3) selecting a DNA sequence from the database prepared; (4) amplifying DNA sequences encoding two or more contiguous peptide domains of FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4; (5) ligating together said amplified DNA sequences to form DNA sequences encoding an antigen specific binding molecule; (6) cloning the amplified DNA obtained into a display vector; and (7) transforming a host with said display vector to produce a library of said antigen specific antigen binding molecules.Type: GrantFiled: February 11, 2019Date of Patent: October 4, 2022Assignee: ELASMOGEN LIMITEDInventors: Caroline Jane Barelle, William James Jonathan Finlay, Alfredo Darman-In-Sheeman, Andrew Justin Radcliffe Porter
-
Publication number: 20200002403Abstract: The present invention provides methods for the production of a library of antigen specific antigen binding molecules having a peptide domain structure represented by the following formula (I): FW 1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 comprising (1) isolating RNA from a member of a species in the Elasmobranchii subclass; (2) amplifying DNA sequences from RNA obtained; (3) selecting a DNA sequence from the database prepared; (4) amplifying DNA sequences encoding two or more contiguous peptide domains of FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4; (5) ligating together said amplified DNA sequences to form DNA sequences encoding an antigen specific binding molecule; (6) cloning the amplified DNA obtained into a display vector; and (7) transforming a host with said display vector to produce a library of said antigen specific antigen binding molecules.Type: ApplicationFiled: February 11, 2019Publication date: January 2, 2020Applicant: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEENInventors: Caroline Jane BARELLE, William James Jonathan FINLAY, Alfredo DARMAN-IN-SHEEMAN, Andrew Justin Radcliffe PORTER
-
Patent number: 10202438Abstract: The present invention provides methods for the production of a library of antigen specific antigen binding molecules having a peptide domain structure represented by the following formula (I): FW 1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 comprising (1) isolating RNA from a member of a species in the Elasmobranchii subclass; (2) amplifying DNA sequences from RNA obtained; (3) selecting a DNA sequence from the database prepared; (4) amplifying DNA sequences encoding two or more contiguous peptide domains of FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4; (5) ligating together said amplified DNA sequences to form DNA sequences encoding an antigen specific binding molecule; (6) cloning the amplified DNA obtained into a display vector; and (7) transforming a host with said display vector to produce a library of said antigen specific antigen binding molecules.Type: GrantFiled: April 23, 2014Date of Patent: February 12, 2019Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEENInventors: Caroline Jane Barelle, William James Jonathan Finlay, Alfredo Darman-In-Sheehan, Andrew Justin Radcliffe Porter
-
Publication number: 20160176951Abstract: The present invention provides methods for the production of a library of antigen specific antigen binding molecules having a peptide domain structure represented by the following formula (I): FW 1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 comprising (1) isolating RNA from a member of a species in the Elasmobranchii subclass; (2) amplifying DNA sequences from RNA obtained; (3) selecting a DNA sequence from the database prepared; (4) amplifying DNA sequences encoding two or more contiguous peptide domains of FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4; (5) ligating together said amplified DNA sequences to form DNA sequences encoding an antigen specific binding molecule; (6) cloning the amplified DNA obtained into a display vector; and (7) transforming a host with said display vector to produce a library of said antigen specific antigen binding molecules.Type: ApplicationFiled: April 23, 2014Publication date: June 23, 2016Inventors: Caroline Jane BARELLE, William James Jonathan FINLAY, Alfredo DARMAN-IN-SHEEHAN, Andrew Justin Radcliffe PORTER
-
Publication number: 20130045208Abstract: The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognising the native signal molecule(s). By binding to signalling molecules, the receptors reduce and maintain extra-cellular concentrations of signal molecules below the threshold level that would otherwise result in certain opportunistic pathogens adopting a virulent form, and can transform virulent organisms to non-virulent states. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease monitoring and management, and in related applications where the host for infection is an animal or plant.Type: ApplicationFiled: April 3, 2012Publication date: February 21, 2013Applicant: Haptogen, Ltd.Inventors: Keith Alan Charlton, Andrew Justin Radcliffe Porter
-
Publication number: 20130011400Abstract: The present invention relates to methods for the killing of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. This has the effect of inducing rapid cell death (autolysis) in the majority of bacterial cells, and preventing virulence or restoring a benign state in surviving cells. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease management, and in related applications where the host for infection is an animal or plant. The compositions described herein are particularly relevant to Pseudomonas aeruginosa infection, for example in the treatment of pulmonary infection in cystic fibrosis patients, and represent a unique bactericidal medication that does not directly target the bacteria.Type: ApplicationFiled: March 5, 2012Publication date: January 10, 2013Applicant: HAPTOGEN LTD.Inventors: Keith Alan Charlton, Andrew Justin Radcliffe Porter, Ian Broadbent
-
Patent number: 8168397Abstract: The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognizing the native signal molecule(s). By binding to signalling molecules, the receptors reduce and maintain extra-cellular concentrations of signal molecules below the threshold level that would otherwise result in certain opportunistic pathogens adopting a virulent form, and can transform virulent organisms to non-virulent states. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease monitoring and management, and in related applications where the host for infection is an animal or plant.Type: GrantFiled: June 2, 2010Date of Patent: May 1, 2012Assignee: Haptogen Ltd.Inventors: Keith Alan Charlton, Andrew Justin Radcliffe Porter
-
Publication number: 20110027280Abstract: The present invention relates to methods for the killing of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. This has the effect of inducing rapid cell death (autolysis) in the majority of bacterial cells, and preventing virulence or restoring a benign state in surviving cells. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease management, and in related applications where the host for infection is an animal or plant. The compositions described herein are particularly relevant to Pseudomonas aeruginosa infection, for example in the treatment of pulmonary infection in cystic fibrosis patients, and represent a unique bactericidal medication that does not directly target the bacteria.Type: ApplicationFiled: July 16, 2010Publication date: February 3, 2011Applicant: HAPTOGEN LTD.Inventors: Keith Alan Charlton, Andrew Justin Radcliffe Porter, Ian Broadbent
-
Publication number: 20100303831Abstract: The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognising the native signal molecule(s). By binding to signalling molecules, the receptors reduce and maintain extra-cellular concentrations of signal molecules below the threshold level that would otherwise result in certain opportunistic pathogens adopting a virulent form, and can transform virulent organisms to non-virulent states. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease monitoring and management, and in related applications where the host for infection is an animal or plant.Type: ApplicationFiled: June 2, 2010Publication date: December 2, 2010Inventors: Keith Alan Charlton, Andrew Justin Radcliffe Porter
-
Patent number: 7812134Abstract: The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognising the native signal molecule(s). By binding to signalling molecules, the receptors reduce and maintain extra-cellular concentrations of signal molecules below the threshold level that would otherwise result in certain opportunistic pathogens adopting a virulent form, and can transform virulent organisms to non-virulent states. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease monitoring and management, and in related applications where the host for infection is an animal or plant.Type: GrantFiled: August 13, 2003Date of Patent: October 12, 2010Assignee: Haptogen Ltd.Inventors: Keith Alan Charlton, Andrew Justin Radcliffe Porter